Clinical trials: Alzheimer Blood Biomarkers, open to volunteers
Alzheimer s Disease, MCI Conversion to Dementia
Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device
This study compares p-tau217 concentrations in blood collected via the Tasso device versus standard venipuncture in subjects with and without Alzheimer's disease, including a subset with confirmed amyloid pathology.
- Conditions
- Alzheimer s Disease, MCI Conversion to Dementia, pTau217, Biomarkers
- Trial name
- NCT07701161
- Where
- 5 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Neurogen Biomarking LLC
Cognitive Decline
TRIAD - Tracking Risk in Integrated Alzheimer's Diagnostics.
The study is based on the hypothesis that the integration of biological, psychological, and social factors, according to the biopsychosocial paradigm, allows for more accurate identification of the different stages of the…
- Trial name
- TRIAD (NCT07399418)
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Alzheimer Disease, Old Age; Dementia
Blood Biomarkers for Alzheimer Disease and Neuro-injury to Estimate the Association With Cognitive/Functional Decline and Mortality in a Real-world Population of GERiatric Hospitalized Patients (BAD-GER)
The BAD-GER study is a multicenter, prospective, three-arm observational study serving to validate a prognostic biomarker algorithm for mortality and hospital readmission; this algorithm will be developed through the…
- Trial name
- BAD-GER (NCT07435467)
- Testing
- collection of blood samples
- Where
- 3 sites in Italy
- Volunteers
- 400 people
- Sponsor
- Istituto Nazionale di Ricovero e Cura per Anziani
Alzheimer's Disease
Acupressure as Long-term Intervention to Slow the Progression of Early/Mild Alzheimer's Disease
This is an assessor-blinded, randomized controlled trial. A total of 188 older adults aged 60-85 years with early/mild Alzheimer's disease (AD) will be recruited from care and attention homes for the elderly and elderly activity…
- Trial name
- NCT07779863
- Testing
- Comfy Acupressure for the Elderly, Least acupressure control
- Where
- Hong Kong
- Volunteers
- 188 people
- Sponsor
- The University of Hong Kong
Alzheimer Disease, Mild Cognitive Impairment (MCI)
Biomarker-based Trial of NPC-1 for Alzheimer's Pathology
This early phase, open label, single arm clinical trial will determine the intraindividual safety, tolerability and effects of NPC1 (parthenolide and ipriflavone) on blood-based biomarkers of Alzheimer's disease (AD) pathology…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD)
- Trial name
- NPC1-AD (NCT07236190)
- Testing
- natural product combination-1 (NPC1)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Subjective Cognitive Decline (SCD)
PENSA+: Extended Follow-up of a Multimodal Lifestyle Intervention to Prevent Cognitive Decline in APOE-ε4 Carriers
PENSA+ is a 5-year follow-up study of participants who previously completed the PENSA clinical trial (NCT03978052), which evaluated an intensive multimodal lifestyle intervention, with or without epigallocatechin gallate (EGCG)…
- Trial name
- PENSA+ (NCT07730671)
- Where
- Spain
- Volunteers
- 121 people
- Sponsor
- Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
Cognitive Decline, Alzheimer Disease
Effects of Real vs. Soundless Acoustic Stimulation During Deep Sleep on Brain Activity, Memory, and Blood Biomarkers in Older Adults (60-85) With Mild Memory Impairment
This study aims to explore a non-invasive way to improve memory and slow cognitive decline in older adults by enhancing sleep quality.
- Conditions
- Cognitive Decline, Alzheimer Disease, Subjective Cognitive Decline (SCD), Mild Cognitive Impairment (MCI)
- Trial name
- NCT06669546
- Testing
- Phase-locked auditory stimulation (PLAS)
- Where
- Switzerland
- Volunteers
- 60 people
- Sponsor
- University of Bern
Alzheimer Disease, Mild Cognitive Impairment
Blood Tests for Alzheimer's Disease: Can Plasma Biomarkers Diagnose and Predict Disease Progression
BLAD is a prospective, monocentric, observational epidemiological study with an additional procedure (annual blood draw) evaluating the diagnostic and prognostic performance of plasma biomarkers for Alzheimer's disease (AD) in a…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Subjective Cognitive Decline, Dementia
- Trial name
- BLAD (NCT07717567)
- Testing
- Annual blood draw for plasma biomarker measurement
- Where
- Italy
- Volunteers
- 2,000 people
- Sponsor
- IRCCS San Raffaele
Alzheimer Disease, Dementia With Lewy Bodies (DLB)
Retrospective Observational Study of Blood-based Biomarkers in the Diagnosis and Monitoring of Patients With a Neurodegenerative Disease or Mental Disorder
This is a retrospective observational study to evaluate the clinical utility of blood-based biomarkers in the diagnosis and management of patients with a neurodegenerative disease (ND) or mental disorder (MD).
- Conditions
- Alzheimer Disease, Dementia With Lewy Bodies (DLB), Frontotemporal Dementia (FTD), Major Depressive Disorder (MDD)
- Trial name
- Synapsing-BK (NCT07314190)
- Where
- Spain
- Volunteers
- 1,799 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Mild Cognitive Impairment, Alzheimer's Disease
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective.
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss
- Trial name
- Bio-Hermes-002 (NCT06584357)
- Testing
- Biomarker Data Collection, MK6240
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- GAP Innovations, PBC
Mild Cognitive Impairment, Alzheimer's Disease
Effects of Ginkgo Biloba on Blood Biomarkers in Mild Cognitive Impairment
This study evaluates the effects of Ginkgo biloba on blood biomarkers related to Alzheimer's disease in patients with mild cognitive impairment.
- Trial name
- NCT07579689
- Testing
- Ginkgo Biloba Extract 240 mg
- Volunteers
- 120 people
- Sponsor
- Hanyang University
Dementia Alzheimers
Blood-based Biomarkers for Diagnosis of Alzheimer's
Alzheimer's disease (AD) may currently be diagnosed using molecular biomarkers in cerebrospinal fluid (CSF) and/or positron emission tomography (PET).
- Trial name
- NCT05187819
- Testing
- predictive value of a blood test
- Where
- Norway
- Volunteers
- 300 people
- Sponsor
- Helse Stavanger HF
Cognitive Dysfunction, Alzheimer Disease
ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults
This randomized, double-blind, placebo-controlled pilot trial will evaluate the effects of alpha-linolenic acid (ALA) supplementation on cognitive function, blood-brain barrier integrity, and brain vascular health in older adults…
- Conditions
- Cognitive Dysfunction, Alzheimer Disease, Blood-Brain Barrier, Apolipoprotein E, Deficiency or Defect of
- Trial name
- NCT07392723
- Testing
- Alpha-Linolenic Acid (2.6 g/day)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Michal Schnaider Beeri, Ph.D.
Mild Cognitive Impairment, Alzheimer Disease
Cognitive Vulnerability to Stress in Individuals at Risk for Alzheimer's Disease
The goal of this clinical trial is to learn about how genetics and the response to stress predicts cognitive decline in individuals with mild cognitive impairment.
- Trial name
- Stress-AD (NCT05795634)
- Testing
- Trier Social Stress Test
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Johns Hopkins University
Alzheimer Disease (AD), Mild Cognitive Impairment (MCI)
REAl World Dementia OUTcomes: Observational Study
READ-OUT observational study will investigate blood-based biomarkers for dementia in real-world clinical settings. This 3-year observational study will include 3165 people, males or females aged 45 years or older, with cognitive…
- Conditions
- Alzheimer Disease (AD), Mild Cognitive Impairment (MCI), Dementia
- Trial name
- READ-OUT (NCT07238049)
- Where
- 27 sites in United Kingdom
- Volunteers
- 3,165 people
- Sponsor
- University of Oxford
Neurodegenerative Diseases, Dementia
Neurofilament Light Chain And Voice Acoustic Analyses In Dementia Diagnosis
This cohort study aims to determine if a blood test can aid with diagnosing dementia in anyone presenting with cognitive complaints to a single healthcare network.
- Trial name
- NAVAIDD (NCT06339190)
- Testing
- Venepuncture
- Where
- 2 sites in Australia
- Volunteers
- 1,000 people
- Sponsor
- Monash University
Major Depressive Disorder (MDD), Schizophenia Disorder
Prospective Observational Study of the Relationship Between Sociodemographic Factors, Blood-based Biomarkers and Psychiatric Symptoms in Neurodegenerative Diseases and Mental Disorders
This is a prospective observational study to identify sociodemographic factors that predict mental health outcomes in the European population and provide evidence linking common, modifiable sociodemographic risk factors for…
- Conditions
- Major Depressive Disorder (MDD), Schizophenia Disorder, Bipolar 1 Disorder, Alzheimer Disease
- Trial name
- Synapsing-SD (NCT07239843)
- Where
- Spain
- Volunteers
- 1,310 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Alzheimer Disease
Wearables-and Blood-based Biomarkers-incorporated Modernisation of Circadian Rhythm Disruption Management in People Living With Alzheimer's Dementia: A Stepwise Study From Digital Inclusivity, Digital Therapy, to Digital Phenotyping and Biomarker Exploration
By 2025, Taiwan will become a super-aged society, with the number of Alzheimer's disease patients continuing to rise. However, the vast majority of dementia patients experience "behavioral and psychological symptoms of dementia"…
- Trial name
- NCT07222449
- Testing
- Photobiomodulation
- Where
- Taiwan
- Volunteers
- 162 people
- Sponsor
- China Medical University Hospital
Cognitive Abnormality
Evaluation of a Decision-Support Tool for Blood Biomarker Testing for Alzheimer's Disease in Primary Care
The goal of the current study is to evaluate a decision-support tool intended to help primary care providers (PCPs) communicate with patients about blood biomarker testing for Alzheimer's Disease, enhancing shared-decision making…
- Trial name
- NCT07812337
- Testing
- Shared decision-making support tool
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Alzheimer Blood Biomarkers, Alzheimer's Disease (AD)
The BRidge Towards Implementation of Blood-based Biomarkers to Enable Early and Accurate Diagnosis of Alzheimer's Disease
Cognitive disorders have a broad differential diagnosis, and a precise, timely diagnosis is essential for personalized treatment and care.
- Trial name
- BRIDGE-AD2 (NCT07680335)
- Testing
- Plasma p-tau217 and neurofilament light chain results
- Where
- 8 sites in Netherlands
- Volunteers
- 550 people
- Sponsor
- Alzheimercentrum Amsterdam